Bharat Serums and Vaccines is looking to repurpose Ulinastatin, a medicine used to treat sepsis and acute pancreatitis, and explore if it can be used in Covid patients who show symptoms of acute respiratory distress.
The company has received the Drug Controller General of India’s approval to undertake late stage Phase III clinical trials in Covid patients showing mild-to-moderate acute respiratory distress symptoms.
The trials should begin shortly in about 120 patients in six to eight hospitals across the country, said Sanjiv Navangul, Managing Director and Chief Executive with Bharat Serums and Vaccines Limited. Data from the trial should be available by the end of the year, he told BusinessLine.
Outlining the reasons for undertaking the study, he said the drug had shown benefits in limiting factors that caused ARDS, and a meta-analysis of about 2300 patients done in China had shown positive outcomes on certain parameters.
It showed an “improvement in oxygenation index, shortening duration of mechanical ventilation, and reduced mortality and ICU stay when compared to conventional therapies”, the company said.
“The drug impacts the mortality and morbidity,” said Navangul, pointing to the key concerns around patients with serious Covid symptoms. The originator of the drug is Japanese company Mochida Pharmaceutical.
“As per the approved clinical trial protocol, subjects with mild-to-moderate Covid-19 will be randomised in the study in a 1:1 ratio with Ulinastatin and standard supportive care or standalone standard supportive care,” said Bharat Serum.
Drugs being tested
While there is no cure or vaccine to tackle Covid, there are a host of drugs being tested and developed by different companies to be used at different stages in the illness – be it the much-discussed hydroxychloroquine to remdesivir and favipiravir.
Ulinastatin is currently manufactured at BSVL’s Ambernath facility in Thane, Maharashtra. The company’s domestic revenues are pegged at about ₹700 crore and it has reasonable exports as well, the official said.
Last year, private equity firm Advent International had picked up a majority stake in the company.
A letter from the Editor
Dear Readers,
The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.
Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.
In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.
We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.
But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.
I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.
A little help from you can make a huge difference to the cause of quality journalism!
Support Quality Journalism